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Background: To explore whether combining inhibitors that target the insulin-like growth factor receptor
(IGFR)/PI3K/Akt/mTOR signaling pathway (vertical blockade) can improve treatment efficacy for hepatocellular
carcinoma (HCC).
Methods: HCC cell lines (including Hep3B, Huh7, and PLC5) and HUVECs (human umbilical venous endothelial
cells) were tested. The molecular targeting therapy agents tested included NVP-AEW541 (IGFR kinase inhibitor),
MK2206 (Akt inhibitor), BEZ235 (PI3K/mTOR inhibitor), and RAD001 (mTOR inhibitor). Potential synergistic antitumor
effects were tested by median dose-effect analysis in vitro and by xenograft HCC models. Apoptosis was analyzed
by flow cytometry (sub-G1 fraction analysis) and Western blotting. The activities of pertinent signaling pathways
and expression of apoptosis-related proteins were measured by Western blotting.
Results: Vertical blockade induced a more sustained inhibition of PI3K/Akt/mTOR signaling activities in all the HCC
cells and HUVEC tested. Synergistic apoptosis-inducing effects, however, varied among different cell lines and drug
combinations and were most prominent when NVP-AEW541 was combined with MK2206. Using an apoptosis array,
we identified survivin as a potential downstream mediator. Over-expression of survivin in HCC cells abolished the
anti-tumor synergy between NVP-AEW541 and MK2206, whereas knockdown of survivin improved the anti-tumor
effects of all drug combinations tested. In vivo by xenograft studies confirmed the anti-tumor synergy between
NVP-AEW541 and MK2206 and exhibited acceptable toxicity profiles.
Conclusions: Vertical blockade of the IGFR/PI3K/Akt/mTOR pathway has promising anti-tumor activity for HCC.
Survivin expression may serve as a biomarker to predict treatment efficacy.
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The multi-kinase inhibitor sorafenib is currently standard
treatment for patients with advanced-stage hepatocellular
carcinoma (HCC) [1,2]. The success of sorafenib trials
encouraged development of many molecular targeted
agents (MTA) that aim at specific molecular derange-
ments in cancer cells or their microenvironment for the
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reproduction in any medium, provided the orclassification of HCC will help not only identification of
potential therapeutic targets in HCC but also patient
enrichment in future clinical trials [3].
The insulin-like growth factor (IGF) signaling pathway
provides an important regulatory mechanism for tumori-
genesis and drug resistance in many cancers, including
HCC [4,5]. Evidence supporting development of inhi-
bitors targeting the IGF signaling pathway for HCC
treatment is three folds. Firstly, many previous studies
linked IGF signaling activity to HCC pathogenesis,
tumor angiogenesis, and drug resistance [6-9]. Secondly,
preclinical studies have shown that the efficacy of anti-
cancer therapy for HCC can be improved by inhibiting. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clinical trials of patients with advanced HCC indicated
that serum IGF levels can help predict efficacy of anti-
angiogenic therapy [13]. However, although many inhibi-
tors of IGF receptors (IGFR) have been developed and
promising antitumor activity has been demonstrated in
pre-clinical studies, clinical studies showed very limited
efficacy of IGFR inhibitors as single-agent therapy in
solid tumors, including HCC [14,15].
An important mechanism of resistance to IGFR inhibi-
tors is the compensatory activation of related signaling
pathways. The PI3K/Akt/mTOR pathway is the most
extensively studied and Akt signaling has been demon-
strated to be a critical mechanism of drug resistance in
HCC cells [16]. Targeting a single point in these pivotal
signaling pathways will induce compensatory up- or
down-stream activation and result in drug resistance
[17,18]. To overcome this compensatory activation,
combination of agents targeting more than one molecule
in a signaling pathway, known as vertical blockade, were
extensively tested in multiple preclinical models and
synergistic anti-cancer efficacy has been demonstrated
[19-21].
In this study, we sought to clarify whether combining
inhibitors that target the IGFR and the PI3K/Akt/mTOR
signaling pathway could enhance therapeutic efficacy in
HCC. The optimal combination of the potential syner-
gistic antitumor activities between IGFR and PI3K/Akt/
mTOR inhibitors were explored. Survivin, an apoptosis-
inhibitory protein that is over-expressed in multiple
cancer types and plays critical roles in regulating
apoptosis, cell proliferation and survival, was found to
be a direct downstream target of the PI3K/Akt/mTOR
pathway. The role of survivin in mediating the anti-tumor
efficacy of IGFR/PI3K/Akt/mTOR vertical blockade was
also examined.
Methods and materials
Cell culture and reagents
The HCC cell lines tested in this study included PLC/
PRF/5 (PLC5), Hep3B (from American Type Culture
Collection), and Huh7 (from Health Science Research
Resources Bank, Japan). Cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum (FBS), penicillin (100 units/mL), and strep-
tomycin (100 μg/mL). Primary human umbilical venous
endothelial cells (HUVEC), which were used to test the
anti-angiogenic activity of the drug combinations, were
cultured as previously described [20]. These cells were
maintained in a humidified incubator under 5% CO2
at 37°C.
The molecular targeted agents (MTAs) tested in this
study included NVP-AEW541 (IGFR inhibitor, Novartis),
MK2206 (Akt inhibitor, MSD), BEZ235 (PI3K/mTORinhibitor, Novartis), and RAD001 (mTOR inhibitor, Novar-
tis). For in vitro experiments, the drugs were dissolved in
DMSO and the final DMSO concentration was kept below
0.1%. For in vivo experiments, the following the optimal
dosage were used: NVP-AEW541 (dissolved in 25 mmol/L
tartaric acid, 30 mg/kg, gavage) once per day for 25 days
based on previous studies [22,23], BEZ235 (dissolved in 10%
NMP (1-methyl-2-pyrrolidone)/PEG300 90%, 25 mg/kg,
gavage) once per day for 25 days based on previous
studies [24,25], and MK2206 (dissolved in 30% captisol,
100 mg/kg, i.p.) once per week for 4 weeks based on
previous studies [26,27]. The antibodies used for Western
blotting, and immunohistochemical staining included
anti-Myc Tag (Origene, Rockville, MD), p-Akt, caspase 3,
p-GSK3β, GSK3β, p-P70S6K, P70S6K, p-4EBP-1, Mcl-1,
Bim, DR-5, FADD (Cell Signaling Technology, Danvers,
MA), Bcl-2, Bad, Bax, survivin, GAPDH, and actin (Santa
Cruz Biotechnology, Santa Cruz, CA).
Tests of in vitro anti-tumor efficacy
Cell viability was assessed by MTT (3-(4, 5-dimethyl-
thiazol-2-yl)-2, 5- diphenyltetrazolium bromide) assay.
The IC50 values after drug treatment were calculated
using CompuSyn software (ComboSyn, Paramus, NJ)
based on changes in absorbance as determined by spec-
trophotometry (DTX 880; Beckman Coulter, Fullerton,
CA). Apoptotic cell death was measured by flow cytom-
etry (sub-G1 fraction analysis) and Western blotting
analysis (caspase activation, PARP cleavage). The poten-
tial synergistic antitumor effects between different drug
treatments were determined by median dose-effect ana-
lysis using the combination index (CI)-isobologram
method, as previously described [20].
Identification of pertinent downstream mediators of
anti-tumor efficacy
The activity of IGFR and the downstream PI3K/Akt/
mTOR signaling pathways was determined by Western
blotting analysis. To explore potential synergistic effects
between IGFR inhibition and other MTAs on the
expression of pertinent apoptosis-related proteins, we
used a human apoptosis array (Proteome Profiler™, R&D
Systems, Minneapolis, MN), which could simultaneously
measure the relative levels of expression of 35 apoptosis-
related proteins (Additional file 1: Figure S1 for the list of
the apoptosis-related proteins analyzed). Signals were vi-
sualized using a UVP Imaging System (UVP, Upland, CA)
or with X-ray film. Candidate molecules were selected
based on their expression levels after drug treatment and
by correlation with in vitro antitumor effects. The ex-
pression levels of these candidate molecules after drug
treatment were confirmed by Western blotting analysis.
To explore the biological roles of the candidate
molecules, small interfering RNA (siRNA) knockdown
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with MTAs treatment. The treated HCC cells were then
collected for Western blotting or flow cytometry
analysis. For the studies of survivin as the downstream
mediator of IGFR/AKT/mTOR vertical blockade, si-survi-
vin (catalog number L-003459-00-0005) and scrambled
nonspecific (negative-control) siRNA (catalog number D-
001810-10-20) were purchased from Thermo Scientific
(Dharmacon Division). HCC cells were transfected
with siRNA using siPORTNeoFx transfection reagent
(Ambion, Austin, TX) and then treated with MTAs.
Over-expression of survivin was done by transiently
transfecting the pCMV6-Myc-DKK-BIRC5 (survivin)
vector (RC205935; Origene Technologies) or empty vector
(pCMV6; Origene Technologies) into HCC cells using
PolyJet transfection reagent (Signagen. Laboratories,
Ijamsville, MD).
Tests of in vivo anti-tumor efficacy
Tumor xenograft experiments were performed using male
BALB/c athymic (nu+/nu+) mice. Hep3B and Huh7 cells
were inoculated subcutaneously at 1 × 106 cells. The pro-
tocol for the xenograft experiments was approved by the
Institutional Animal Care and Use Committee of the
College of Medicine, National Taiwan University, and
conformed to the criteria outlined in the Guide for the
Care and Use of Laboratory Animals prepared by the
National Academy of Sciences and published by the
National Institutes of Health. The mice were randomized
to different MTA treatment groups when tumor vol-
ume reached approximately 100 mm3 (volume [mm3] =
[width]2 × length × 0.5) (animal number n ≥ 5 in each
group). NVP-AEW541 and BEZ235 treatments were
administered daily by gavage. MK2206 was administered
weekly by intraperitoneal injection. Tumor volume and
body weight were recorded every 5 days. After MTAs treat-
ment, fresh-frozen tumor samples were collected for deter-
mination of levels of various proteins by Western blotting.
After drug treatment, formalin-fixed, paraffin-embedded
tumor samples were collected for immunohistochemical
analysis of protein expression and tumor angiogenesis.
TUNEL assay was performed to measure the extent of
tumor cell apoptosis, as previously described [20].
Statistical analysis
All data used were representative of at least three independ-
ent experiments. Quantitative data are expressed as mean
± SD. Comparisons were analyzed using the Student’s t test
and ANOVA. Significance was defined as p < 0.05.
Results
In vitro anti-tumor efficacy of IGFR/PI3K/Akt/mTOR inhibition
The growth-inhibitory effects of NVP-AEW541 (IGFR in-
hibitor), MK2206 (Akt inhibitor), BEZ235 (PI3K/mTORdual inhibitor), and RAD001 (mTOR inhibitor) on HCC
cells and HUVEC were shown in Figure 1A. The response
of the HCC cell lines tested to individual MTAs did not
differ significantly from one another. BEZ235 appeared to
be the most potent inhibitor of PI3K/Akt/mTOR signaling
activity (Figure 1B). BEZ235 inhibited Akt, GSK3β, and
P70S6K phosphorylation at submicromolar range, consist-
ent with its growth-inhibitory effects. On the other hand,
although RAD001 inhibited the downstream P70S6K
phosphorylation at submicromolar levels, the Akt and
GSK3βphosphorylation appeared increased after RAD001
treatment, suggesting compensatory activation of up-
stream signaling activities (Figure 1B). This finding may
explain the relatively poor growth-inhibitory effects of
RAD001 in the HCC cells tested (IC50 > 10 μM).
To investigate the potential synergistic antitumor
effects of vertical blockade of the IGFR/PI3K/Akt/
mTOR signaling pathway, median effect analysis was
performed to measure the combination index (CI) of
different treatments combining NVP-AEW541, MK2206,
BEZ235, and RAD001, with CI values <1 indicating syn-
ergy (Figure 2A). Synergistic growth-inhibitory effects
were seen for most of the combinations tested in all
three HCC cell lines and in HUVECs. Synergistic
apoptosis-inducing effects, measured by flow cytometry
(sub-G1 fraction analysis) and Western blotting (PARP
cleavage and caspase 3 activation), were most consistent
when NVP-AEW541 was combined with the Akt inhibi-
tor MK2206 (Figure 2B and C). BEZ235 and RAD001
could enhance apoptosis in Hep3B and HUVECs only
when combined with NVP-AEW541 (Figure 2B).
Survivin is an important downstream mediator of anti-
tumor synergy
To explain the differential effects on apoptosis induction
by different drug combination, we first compared the
effects of these combinations on activity of PI3K/Akt/
mTOR pathway in Hep3B and Huh7 cells. As shown
in Figure 3A, all the combinations, including NVP-
AEW541-MK2206, NVP-AEW541-BEZ235, and NVP-
AEW541-RAD001, inhibited the phosphorylation of Akt,
P70S6K, and 4EBP-1 to a similar extent in Hep3B and
Huh7 cells. Therefore, the difference in apoptosis in-
duction by different drug combination in the 2 cell lines
cannot be explained by their inhibitory effects on PI3K/
Akt/mTOR signaling activity alone. Similarly, the effects
of these drug combinations on expression of apoptosis-
related proteins, including mcl-1, bcl-2, bim, bad, and bax,
were also similar in the 2 cell lines (Figure 3B).
The apoptosis protein array was then used to explore
potential mediators of anti-tumor activity of different
drug combinations targeting the IGFR/AKT/mTOR
pathway. Survivin was identified as the candidate mol-
ecule because it showed the most consistent inhibition
Figure 1 Growth-inhibitory and downstream signaling effects of molecular targeted agents (NVP-AEW-541, IGFR inhibitor; MK2206,
Akt inhibitor; BEZ235, PI3K/mTOR inhibitor; RAD001, mTOR inhibitor) on HCC cells and HUVECs. (A) IC50 of HCC cell lines and HUVECs
after drug treatments. Cells in 96-well plates were treated with drugs at the indicated concentrations for 72 h, and cell viability was assessed by
MTT assay. Points, mean averages (n = 3); bars, SD. (B) Effects on Akt, GSK3β, P70S6K phosphorylation were examined by Western blotting in
HCC cells and HUVECs after 24-hour drug treatments at the indicated concentrations.
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BEZ235, or RAD001 and correlated with the anti-tumor
synergy (Additional file 1: Figure S1). This finding was
confirmed by Western blotting (Figure 4A). Furthermore,in Huh7 cells inhibition of survivin expression was more
prominent in NVP-AEW541/MK2206 combination than
in NVP-AEW541/BEZ235 and NVP-AEW541/RAD001
combinations (Figure 4A). This finding suggested that the
Figure 2 (See legend on next page.)
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Figure 2 Synergistic growth-inhibitory and apoptosis-inducing effects between the IGFR inhibitor NVP-AEW541 and PI3K/Akt/mTOR
inhibitors (MK2206, BEZ235, and RAD001). (A) Median dose-effect analysis of synergistic growth-inhibitory effects. Growth inhibition was
measured by MTT assay. CI was calculated using the CI-isobologram method; CI = 1, additive effect; CI < 1, synergistic effect; CI > 1, antagonistic
effect. The concentrations of the drug used for MTT assay and the original CI (combination index) values of each drug combination were
summarized in Additional file 1: Table S1. (B and C) Synergistic apoptosis-inducing effects between NVP-AEW541 and MK2206, BEZ235, and
RAD001 in HCC cells and HUVECs measured by flow cytometry (sub-G1 fraction analysis, B) and by PARP cleavage and caspase3 activation
(Western blotting, C). Columns, mean averages of three independent experiments; bars, SD. **, p < 0.01 compared with cells treated with a
single inhibitor.
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cells can be explained at least in part by their inhibitory
effects on survivin expression.
The role of survivin as an important downstream
mediator was further explored by siRNA knockdown
and transient over-expression experiments. Suppression
of survivin expression enhanced the apoptosis-indu-
cing effects of all 3 combinations, and the effects of
NVP-AEW541/BEZ235 and NVP-AEW541/RAD001
combinations were enhanced to be similar to that of
NVP-AEW541/MK2206 combination (Figure 4B). In
addition, over-expression of survivin decreased the
apoptosis-inducing effects of NVP-AEW541/MK2206
combination, whereas the effects on NVP-AEW541/
BEZ235 and NVP-AEW541/RAD001 combinations were
less obvious in Huh7 (Figure 4C), and over-expression
of survivin decreased the apoptosis-inducing effects of
NVP-AEW541/MK2206, NVP-AEW541/BEZ235 and
NVP-AEW541/RAD001 combination (Additional file 1:
Figure S2). The above data supports the role of survivin as
an important downstream mediator of anti-tumor synergy
of vertical blockade of IGFR/PI3K/Akt/mTOR signaling
pathway.
In vivo confirmation of efficacy of vertical blockade
The antitumor synergy of vertical blockade of IGFR/PI3K/
Akt/mTOR signaling pathway was also confirmed by
xenograft experiments. Combination of NVP-AEW541
and MK2206 produced the most prominent anti-tumor
effects in both Hep3B and Huh7 models (Figure 5A), asso-
ciated with a significant increase in tumor cell apoptosis
and suppression of survivin expression than single-agent
treatment. By contrast, combination of NVP-AEW541
and BEZ235 produced synergistic anti-tumor effects in
Hep3B but not in Huh7 models, consistent with the
in vitro study results. The changes of tumor microvessel
density showed similar trends in Hep3B and Huh7 models
(Additional file 1: Figure S3), suggesting that the in vivo
effects of vertical blockade was mainly on cancer cells per
se. Drug treatment induced body weight loss, which
appeared more prominent in treatments containing the
Akt inhibitor MK2206 (Additional file 1: Figure S4). How-
ever, no significant abnormalities of hemogram or blood
biochemistry tests were found in any of the treatmentgroups, suggesting that the combination treatment has an
acceptable safety profile.
Discussion
In this study we explored whether vertical blockade that
targets both the IGFR and the PI3K/Akt/mTOR signal-
ing pathway can enhance therapeutic efficacy for HCC.
Our data indicated that combining the IGFR inhibitor
NVP-AEW541 with inhibitors against PI3K/Akt/mTOR
pathway (MK2206 or BEZ235) results in synergistic anti-
tumor effects in HCC cells in vitro and in vivo. Survivin
is an important mediator of this anti-tumor synergy. The
combination treatments have acceptable safety profile.
Therefore, further clinical trials to explore their clinical
efficacy are warranted.
Vertical blockade of the PI3K/Akt/mTOR pathway has
been extensively studied to overcome the compensatory
activation induced by single-agent treatment [24,28].
The synergistic anti-tumor effects were associated with a
more sustained inhibition of PI3K/Akt/mTOR signaling
activity and down-stream regulators of cell growth, in-
cluding myc, cyclin D, and retinoblastoma (RB) protein.
Synergistic anti-angiogenic effects of the vertical block-
ade strategy have also been demonstrated in both
in vitro and in vivo. It should be clarified whether the
more sustained inhibition of PI3K/Akt/mTOR signaling
activity is also associated with more treatment-related
toxicities in cancer patients. The synergistic apoptosis-
inducing effects in normal cells like HUVEC also im-
plied potential synergistic toxicity. Early-phase clinical
trials of agents targeting single points along the IGFR/
PI3K/Akt/mTOR pathway reported only mild to mo-
derate adverse events, including hyperglycemia, fatigue,
skin rashes and gastrointestinal toxicities [29]. While
pre-clinical studies of various combinations of these
agents did not report excessive overlapping toxicity
profiles, the safety of long-term use of the combination
treatments in cancer patients must be carefully evaluated.
Another important issue in designing clinical trials for
MTAs is patient enrichment, i.e., selection of patients
who will most likely benefit from the MTAs under
evaluation. Activation of IGFR and PI3K/Akt/mTOR
pathways has been shown to indicate rapid tumor
progression and poor prognosis in HCC [30]. Activation
Figure 3 The effects of combinations of NVP-AEW541 with MK2206, BEZ235, or RAD001 inhibitors on downstream signaling activity
(A) and apoptosis-related proteins (B) in HCC cells. Effects on phosphorylation of Akt, P70S6K, and 4EBP-1 were examined by Western blotting.
HCC cells (Hep3B and Huh7) were treated with or without NVP-AEW541 and MK2206, BEZ235, or RAD001 at the indicated concentrations and
times. Whole-cell lysates were subjected to Western blotting.
Ou et al. Molecular Cancer 2014, 13:2 Page 7 of 11
http://www.molecular-cancer.com/content/13/1/2of this pathway is usually determined by immunohisto-
chemical studies of protein phosphorylation in HCC
tumor tissue, because genetic aberrations of IGFR and
PI3K/Akt/mTOR pathways are rare in HCC [31,32].However, such immunohistochemical studies are not re-
liable in HCC due to protein instability and difficulty in
standardization of tissue processing [33,34]. The lack of
reliable biomarkers for patient enrichment may partly
Figure 4 Survivin is a possible mediator of antitumor synergy between NVP-AEW541 and MK2206, BEZ235, and RAD001. (A) Effects
between NVP-AEW541 and MK2206, BEZ235, and RAD001 on survivin expression in HCC cells. HCC cells (Hep3B and Huh7) were treated with
NVP-AEW541, MK2206, BEZ235, and RAD001 at the indicated concentrations for 48 hours. Whole-cell lysates were subjected to Western blotting.
(B) Survivin knockdown enhanced the efficacy of vertical blockade. Huh7 cells were transfected with si-survivin or scrambled siRNA for 24 hours,
and then treated with different drug combination as indicated. (C) Huh7 cells were transfected with V-Survivin (pCMV6-Myc-DKK-survivin) or
empty vectors for 8 hours, and then treated with different drug combination as indicated. Whole-cell lysates were collected for Western blotting
after 48-hour drug treatment. The percentages of apoptotic cells were measured by flow cytometry after 72-hour drug treatment. Columns, mean
of three independent experiments; bars, SD. **, p < 0.01.
Ou et al. Molecular Cancer 2014, 13:2 Page 8 of 11
http://www.molecular-cancer.com/content/13/1/2explain the lack of success of IGFR inhibitors in previous
clinical trials [4,14,15].
The correlation of survivin suppression and anti-
tumor synergy found in our study suggest that survivin
expression may be a good biomarker for treatment
targeting the IGFR/PI3K/Akt/mTOR pathway. Future
clinical trials may integrate evaluation of survivin in
HCC tumor tissue to clarify whether baseline levels of
survivin expression can serve as predictive biomarkers
for treatment efficacy. Survivin has been reported as a
direct downstream target of the PI3K/Akt/mTOR
pathway and plays an important role in induction of
drug resistance [35,36]. In this study, although verticalblockade produced sustained suppression of signaling
activities in the IGFR/PI3K/Akt/mTOR pathway of all
the HCC cells tested, the impact on survivin expression
and subsequent anti-tumor synergy varied among differ-
ent combinations and cell lines. It has been demonstrated
that vertical blockade of the PI3K/Akt/mTOR pathway
can induce profound changes in gene expression inde-
pendent of PI3K/Akt/mTOR signaling activities [28].
Moreover, survivin expression is regulated by a complex
intra-cellular signaling network involving the PI3K/Akt/
mTOR, RAF/MAPK/ERK, NFκB, and hypoxia-inducible
factor (HIF)-1α [37]. Therefore, it is likely that the effects
of IGFR/PI3K/Akt/mTOR vertical blockade on survivin
Figure 5 In vivo antitumor synergy between NVP-AEW541, MK2206 and BEZ235. Hep3B and Huh7 cells were subcutaneously injected
into male BALB/c athymic nude mice. Mice were treated as indicated (NVP, NVP-AEW-541 30 mg/kg/day by gavage; MK2206, MK2206 100 mg/kg/
week by intra-peritoneal injection; BEZ, BEZ235 25 mg/kg/day by gavage). Values presented are the means ± SD (n = 5 in each group). (A) Differences
in tumor growth. (B) Differences in tumor cell apoptosis (TUNEL assay).*, p < 0.05; **, p < 0.01, compared with the control (vehicle-treated) group.
(C) Difference in survivin measured by Western blotting of tumor lysates.
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interactions of the cellular signaling network. Survivin
expression, which acts as an integration of the cellu-
lar signals determining cellular proliferation, survival,
and drug resistance, will therefore become a more
direct biomarker to predict and monitor treatment
response.Conclusion
In summary, our data indicates that combination of
inhibitors targeting IGFR and the PI3K/Akt/mTOR
pathway can improve treatment efficacy for HCC
in vitro and in a xenograft mouse model in vivo.
Survivin expression can serve as a biomarker to predictthe anti-tumor synergy. The efficacy and safety of the
combination treatments should be explored by future
clinical trials.Additional file
Additional file 1: Figure S1. (A) The list of apoptosis-related proteins
measured by the Human Apoptosis Array kit (Proteome ProfilerTM, R&D
Systems, Minneapolis, MN). (B) Evaluation of effects of different drug
combinations on expression of apoptosis-related proteins. Figure S2.
Survivin is a possible mediator of antitumor synergy between NVP-
AEW541 and MK2206, BEZ235, and RAD001. Figure S3. In vivo tumor
angiogenesis between NVP-AEW541, and MK2206 and BEZ235 inhibitors.
Figure S4. Assessment of the in vivo toxicities. Table S1. Median dose
effect analysis of synergistic growth inhibitory effects of NVP-AEW541/
MK2206, NVP-AEW541/ BEZ235 and NVP-AEW541/ RAD001.
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